Efficacy of Memantine ER on Activities of Daily Living: A Post Hoc Responder Analysis From a Randomized Trial in Patients With Moderate-to-severe Alzheimer's Disease

被引：0

作者：

Alva, Gustavo ^{[1
]}

Grossberg, George ^{[2
]}

Hendrix, Suzanne ^{[3
]}

Ellison, Noel ^{[3
]}

Andersen, Kristen A. ^{[4
]}

Edwards, John ^{[5
]}

机构：

[1] ATP Clin Res, Costa Mesa, CA USA

[2] St Louis Univ, St Louis, MO 63103 USA

[3] Pentara Corp, Salt Lake City, UT USA

[4] Prescott Med Commun Grp, Chicago, IL USA

[5] Allergan Plc, Jersey City, NJ USA

来源：

NEUROLOGY | 2017年 / 88卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P3.087

引用

页数：2

共 50 条

[1] Benefits of Extended-Release Memantine in Moderate-to-Severe Alzheimer's Disease as a Function of Disease Severity: Post Hoc Analysis from a Randomized Trial
Tocco, Michael
Hendrix, Suzanne
Miller, Michael L.
Pejovio, Vojislav
Graham, Stephen M.
ANNALS OF NEUROLOGY, 2013, 74 : S92 - S93
[2] Extended-Release Memantine (28 mg, Once Daily) and Sustained Behavioral Improvement: Post hoc Responder Analysis From a Randomized Trial in Patients With Moderate to Severe Alzheimer's Disease
Cummings, Jeffrey L.
Hendrix, Suzanne
Miller, Michael
Pejovic, Vojislav
Graham, Stephen M.
Tocco, Michael
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2012, 20 (03): : S130 - S130
[3] Extended-Release Memantine (28 mg, Once Daily) and Sustained Behavioral Improvement: Post Hoc Responder Analysis from a Randomized Trial in Patients with Moderate to Severe Alzheimer's Disease
Cummings, Jeffrey
Hendrix, Suzanne
Miller, Michael
Pejovic, Vojislav
Graham, Stephen
Tocco, Michael
NEUROLOGY, 2012, 78
[4] Memantine and individual activities of daily living in moderate to severe Alzheimer's disease
Feldman, H
Schmitt, FA
Doraiswamy, PM
Graham, SM
Bell, JM
NEUROLOGY, 2005, 64 (06) : A103 - A104
[5] Memantine and individual activities of daily living in moderate to severe Alzheimer's disease
Feldman, H
Schmitt, E
Pfeiffer, E
Graham, SM
Bell, JM
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S570 - S570
[6] Memantine and individual activities of daily living in moderate to severe Alzheimer's disease
Feldman, H
Schmitt, F
Pfeiffer, E
Graham, S
Bell, J
INTERNATIONAL PSYCHOGERIATRICS, 2005, 17 : 200 - 201
[7] Extended-release memantine (28 mg, once daily) and sustained cognitive improvement: Post hoc responder analysis from a randomized trial in patients with moderate to severe Alzheimer's disease.
Tocco, M.
Hendrix, S.
Miller, M. L.
Pejovic, V.
Graham, S. M.
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2012, 60 : S197 - S197
[8] Memantine and individual activities of daily living in moderate to severe Alzheimer's disease.
Feldman, H
Schmitt, F
Doraiswamy, P
Graham, SM
Bell, JM
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (04) : S26 - S26
[9] Activities of daily living in moderate-to-severe Alzheimer disease: An analysis of the treatment effects of memantine in patients receiving stable donepezil treatment
Feldman, Howard H.
Schmitt, Frederick A.
Olin, Jason T.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 2006, 20 (04): : 263 - 268
[10] Post-hoc responder analyses of memantine treatment on behavioural disturbances in patients with moderate to severe Alzheimer's disease (AD)
Cummings, J.
Stender, K.
EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 36 - 36

← 1 2 3 4 5 →